STOCK TITAN

MediWound to Present at Upcoming Investor Conferences in February

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MediWound Ltd. (Nasdaq: MDWD) announced its participation in two investor conferences in February 2022. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 8:30 am ET, featuring a fireside chat. The second is the Aegis Virtual Investor Conference on February 24, 2022, at 3:00 pm ET. Investors can access replays on the company’s Events page. MediWound focuses on bio-therapeutic solutions for tissue repair and offers products like NexoBrid® and EscharEx®.

Positive
  • None.
Negative
  • None.

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows:

BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Date:Wednesday, February 16, 2022
Time:8:30 am ET
Format:Fireside Chat
Registration Link:Click here
  
Aegis Virtual Investor Conference
Date:Thursday, February 24, 2022
Time:3:00 pm ET
Link:Aegis Virtual Conference Calendar

A replay of the fireside chat and presentation will be available on the Events page of the MediWound Investor Relations website at https://ir.mediwound.com/events-and-presentations.

About MediWound Ltd.
MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.

NexoBrid®, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

EscharEx®, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.

MW005®, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.

Contacts:
Boaz Gur-LavieMonique Kosse
Chief Financial OfficerManaging Director, LifeSci Advisors
MediWound Ltd. 212-915-3820
ir@mediwound.com monique@lifesciadvisors.com 

FAQ

What is MediWound presenting at the February 2022 investor conferences?

MediWound will present at the BTIG MedTech Conference on February 16 and the Aegis Virtual Investor Conference on February 24, 2022.

When is MediWound's BTIG MedTech Conference presentation scheduled?

The BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference presentation is on February 16, 2022, at 8:30 am ET.

What time is the Aegis Virtual Investor Conference presentation by MediWound?

MediWound's presentation at the Aegis Virtual Investor Conference is scheduled for February 24, 2022, at 3:00 pm ET.

Where can I watch MediWound's conference presentations?

Replays of MediWound's conference presentations can be found on their Events page at https://ir.mediwound.com/events-and-presentations.

What products does MediWound focus on for tissue repair?

MediWound focuses on bio-therapeutic solutions including NexoBrid® for burn care and EscharEx® for chronic wound treatment.

MediWound Ltd.

NASDAQ:MDWD

MDWD Rankings

MDWD Latest News

MDWD Stock Data

184.40M
7.79M
19.75%
45.5%
5.5%
Biotechnology
Healthcare
Link
United States of America
Yavne